396 related articles for article (PubMed ID: 20970951)
1. The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice.
Fukuda D; Enomoto S; Hirata Y; Nagai R; Sata M
Biomed Pharmacother; 2010 Dec; 64(10):712-7. PubMed ID: 20970951
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Takaya T; Kawashima S; Shinohara M; Yamashita T; Toh R; Sasaki N; Inoue N; Hirata K; Yokoyama M
Atherosclerosis; 2006 Jun; 186(2):402-10. PubMed ID: 16157344
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in murine atherosclerosis.
Nagy N; Melchior-Becker A; Fischer JW
Basic Res Cardiol; 2010 Jan; 105(1):29-38. PubMed ID: 19701787
[TBL] [Abstract][Full Text] [Related]
4. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages.
Matsumura T; Kinoshita H; Ishii N; Fukuda K; Motoshima H; Senokuchi T; Taketa K; Kawasaki S; Nishimaki-Mogami T; Kawada T; Nishikawa T; Araki E
Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1268-75. PubMed ID: 21474824
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of the AT2 receptor reduced atherogenesis in ApoE(-/-)/AT1A(-/-) double knock out mice.
Tiyerili V; Mueller CF; Becher UM; Czech T; van Eickels M; Daiber A; Nickenig G; Wassmann S
J Mol Cell Cardiol; 2012 Mar; 52(3):630-7. PubMed ID: 22230040
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
[TBL] [Abstract][Full Text] [Related]
7. AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARγ.
Tiyerili V; Becher UM; Aksoy A; Lütjohann D; Wassmann S; Nickenig G; Mueller CF
Cardiovasc Diabetol; 2013 Feb; 12():30. PubMed ID: 23374104
[TBL] [Abstract][Full Text] [Related]
8. Deletion of angiotensin II type I receptor reduces hepatic steatosis.
Nabeshima Y; Tazuma S; Kanno K; Hyogo H; Chayama K
J Hepatol; 2009 Jun; 50(6):1226-35. PubMed ID: 19395110
[TBL] [Abstract][Full Text] [Related]
9. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice.
Blessing E; Preusch M; Kranzhöfer R; Kinscherf R; Marx N; Rosenfeld ME; Isermann B; Weber CM; Kreuzer J; Gräfe J; Katus HA; Bea F
Atherosclerosis; 2008 Aug; 199(2):295-303. PubMed ID: 18093593
[TBL] [Abstract][Full Text] [Related]
10. Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice.
Fukuda D; Sata M; Ishizaka N; Nagai R
Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):90-6. PubMed ID: 17962627
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
Ihara Y; Egashira K; Nakano K; Ohtani K; Kubo M; Koga J; Iwai M; Horiuchi M; Gang Z; Yamagishi S; Sunagawa K
J Mol Cell Cardiol; 2007 Oct; 43(4):455-64. PubMed ID: 17761193
[TBL] [Abstract][Full Text] [Related]
12. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation.
Fukuda D; Enomoto S; Nagai R; Sata M
Biomed Pharmacother; 2009 Dec; 63(10):754-61. PubMed ID: 19304450
[TBL] [Abstract][Full Text] [Related]
14. Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions.
Nenicu A; Körbel C; Gu Y; Menger MD; Laschke MW
Hum Reprod; 2014 May; 29(5):1011-24. PubMed ID: 24578472
[TBL] [Abstract][Full Text] [Related]
15. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620
[TBL] [Abstract][Full Text] [Related]
16. Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis.
Schlimmer N; Kratz M; Böhm M; Baumhäkel M
Br J Pharmacol; 2011 Jun; 163(4):804-14. PubMed ID: 21323898
[TBL] [Abstract][Full Text] [Related]
17. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
[TBL] [Abstract][Full Text] [Related]
18. Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E-/- mice.
Aono J; Suzuki J; Iwai M; Horiuchi M; Nagai T; Nishimura K; Inoue K; Ogimoto A; Okayama H; Higaki J
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1453-9. PubMed ID: 22460554
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gain.
Aubert G; Burnier M; Dulloo A; Perregaux C; Mazzolai L; Pralong F; Zanchi A
Metabolism; 2010 Jan; 59(1):25-32. PubMed ID: 19793594
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.
Toba H; Tojo C; Wang J; Noda K; Kobara M; Nakata T
Eur J Pharmacol; 2012 Jun; 685(1-3):91-8. PubMed ID: 22314223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
